SOST and chronic kidney disease: In addition, sclerostin, a Wnt signaling pathway inhibitor, has been shown to be an important messenger in the cross-talk between bone and the vasculature, and the VC and fractures as well.[44, 45] In one phase II study, using romosozumab (a humanized monoclonal antibody to sclerostin) to treat 419 osteoporotic women, the results are promising; however the long-term (>12 months) effect is unknown.[46] Furthermore, a sclerostin inhibitor probably worsens VC in CKD rats [47] and may lead to deterioration of human renal function [33].